"进入老龄化社会，阿尔茨海默病（大家常说的老年痴呆）越来越受大众关注。阿尔茨海默病一旦进入 中重度就难以逆转，因此早筛查、早干预是非常重要。"宁玉萍向羊城晚报记者介绍，"5G脑心动车就 是希望打破空间限制，把移动式脑健康智慧服务，送到有需要的人身边。" 羊城晚报记者 林清清 通讯员 张舒维 傅文臻 林冬霓 一辆车、一顶帽、一管血……上车半小时，就能快速检测是否老年痴呆，还能在车上进行各种人机互动 训练！ 在广东，一辆融合搭载了10多项专利技术成果的全球首辆5G脑心动车，自去年8月落地就备受瞩目，11 月开进全运会会场，12月又开赴揭阳、普宁。据记者了解，今年它将开到福建龙岩、西藏林芝、云南大 理等地，并不断升级技术，从粤港澳大湾区核心区向外稳步辐射，提供脑健康智慧服务的输出标准样 本，打造可复制的"广东方案"。近日，记者采访该医工结合的研发团队，解密"广东智造"背后的"科技 向善"力量。 一辆车：搭载10余项专利技术成果 "我要把结果带回去给家人看看，让他们也重视脑健康！"在广州白云山上，爱运动的60多岁王大姐，登 上5G脑心动车，只花了15分钟就完成了测试。 脑机接口15分钟快测、最快3分钟可出报告、一管血 ...

Core Insights - The company has several noteworthy events to watch in the coming months regarding its stock performance [1] Recent Events - The company's cervical cytology AI class III certification is expected to be approved between late March and early April 2026, which may provide a monetization opportunity for its AI-assisted diagnostic business [2] - Nanjing Qianjing Venture Capital Partnership announced on January 18, 2026, its plan to reduce its holdings by up to 1.61% of the company's total share capital, necessitating attention to the implementation progress [2] Company Status - The management expressed confidence in returning to positive growth and achieving net profit recovery in 2026, primarily based on business adjustments and AI initiatives [3] Policy Environment - The National Healthcare Security Administration's guideline released in December 2025 regarding the pricing of pathological medical services may stimulate demand for digital pathology tools, although specific pricing will require negotiations with local authorities [4] Stock Price Situation - Technical analysis indicates that the stock price has recently tested Fibonacci resistance levels, with overbought stochastic indicators suggesting a potential short-term bearish correction risk [5] Future Development - The company plans to launch new pathology AI products annually starting in 2028 to enhance its product line [6]

Core Viewpoint - The launch of online first consultation services by Beijing Children's Hospital and Capital Institute of Pediatrics marks a significant step in enhancing healthcare accessibility and efficiency, particularly in pediatric care [1][2]. Group 1: Online First Consultation Services - Starting January 2026, Beijing will initiate a one-year pilot program for online first consultations in pediatric growth, nutrition, and skin disease specialties [1]. - The transition from online follow-up to first consultation is seen as a crucial advancement in providing quality medical services [1]. Group 2: Demand and Limitations - The previous restriction on online first consultations was primarily for safety reasons, as comprehensive examinations are challenging in a virtual setting, leading to potential misdiagnosis in complex cases [1][2]. - The demand for online first consultations is increasing, especially among patients in remote areas or those with mobility issues, highlighting the need for a more comprehensive service model [2]. Group 3: Management and Implementation - Breaking the first consultation limitation will require stronger management and clear guidelines on which diseases are suitable for online consultations [3]. - The pilot program will set high standards for the qualifications and clinical experience of physicians involved in online first consultations [3]. Group 4: Future Prospects - The pilot program is expected to inject new momentum into internet-based healthcare, potentially leading to innovations in service delivery as key elements like prescription rights and insurance payments are streamlined [4]. - The integration of technologies such as electronic medical records and AI-assisted diagnosis will expand the scope of internet-based medical services, enhancing both quality and convenience [4].

Core Viewpoint - The company, Jiukang Biotechnology, has evolved from a代理商 to a leading player in the IVD (in vitro diagnostics) industry in China, focusing on innovation and precision diagnosis to drive future growth [2][3]. Group 1: Company Development - Jiukang Biotechnology started as an代理商 for an international IVD brand and quickly gained recognition, becoming a service supplier for the national quality control products [3]. - The company has maintained a strong client base, with over 70% of top-tier hospitals in China being loyal customers [3]. - The company has significantly increased its R&D investment, with R&D accounting for 21% of sales revenue in the first three quarters of 2025, up from 14% in the same period of 2024 [3]. Group 2: Product Innovation - R&D efforts are focused on new products in areas such as pathology, chemiluminescence, and coagulation, leading to an increase in medical device registrations and patents [4]. - The company has launched new products, including a high-speed fully automated chemiluminescence immunoassay analyzer and a biochemical analyzer, enhancing its competitive edge in the market [4]. - Jiukang's first AI project, a prostate cancer AI interpretation software, has been developed and validated, with plans to expand into smart pathology products [4]. Group 3: Strategic Partnerships - The company aims to become a platform enterprise in the IVD sector, collaborating with leading international firms to leverage their strengths and expand into global markets [5]. - A strategic partnership with Abbott began in 2013, allowing Jiukang to share its patented processes for global product production, resulting in profit-sharing [6]. - In 2020, a significant partnership with China National Pharmaceutical Group (Sinopharm) was established, enhancing sales channels and accelerating growth, with Sinopharm becoming the largest shareholder [6]. Group 4: Industry Trends - The IVD industry in China is rapidly developing, with significant growth potential driven by medical reform and innovation [7]. - The industry is expected to undergo a transformation towards high-quality upgrades, with a focus on value competition rather than price competition [7]. - Emerging technologies such as molecular diagnostics and AI-assisted diagnostics are anticipated to become core competitive advantages, with an emphasis on domestic alternatives in high-end markets [7].

Summary of the Conference Call for Anbiping Company Overview - **Company**: Anbiping - **Industry**: AI-assisted diagnostics in healthcare, specifically focusing on cervical cytology and pathology services Key Points and Arguments AI Model Development and Regulatory Progress - Anbiping's cervical cytology AI model has submitted a Class III medical device application, expected to be approved by the end of March or early April 2026, having completed over 6,000 clinical trials and published research in international journals, indicating strong competitiveness [2][5][11] - The company plans to implement a per-use charging model in the domestic market by the end of 2026 after obtaining the Class III certification, believing this model has greater market potential compared to a one-time purchase model [2][7] Market Opportunities and Policy Support - National policies support AI-assisted diagnostics being included in medical insurance, with local price increases for immunohistochemistry diagnostics observed in Chongqing, although the implementation varies by region [2][6] - The company is developing additional AI-enabled products in areas such as HE Pusang, gastric cancer, and breast cancer, with specific directions to be determined in the first half of 2026 [2][8] Financial Performance and Challenges - The overall business performance in 2025 is expected to be poor, with a downward trend in revenue due to the impact of HPV centralized procurement and an increase in VAT on certain product lines, affecting gross and net profit margins [3] - The direct sales to distribution transition has faced challenges, including price reductions and customer attrition, leading to declines in both revenue and profit [3] Revenue Growth and Projections - The revenue growth guidance for 2026 is approximately 20%, supported by low base effects, the clearing of HPV centralized procurement, and the gradual implementation of the direct sales to distribution strategy [4][25] - The pathology co-construction business aims to increase revenue from over 20 million yuan in 2025 to over 50 million yuan in 2026, with an expected growth rate of 40-50% [2][15] AI and Digital Solutions - The company is focusing on enhancing its digital solutions and plans to implement per-use charging at pathology co-construction points, aiming to integrate digital products into these locations [17][18] - Anbiping is also developing a pathology app similar to ChatGPT, targeting doctors, with a demo expected to launch in mid-2026 [10] Competitive Landscape and Future Outlook - The company currently does not see significant competition in its established pathology co-construction areas, which is favorable for its market position [19] - Anbiping is preparing for increased competition in the AI diagnostics market but remains focused on its product development and sales strategies [20][21] Financial Management and Investment Plans - The company plans to maintain a stable increase in net profit margins, targeting a long-term goal of 15%, although specific annual increases will require further assessment [30] - Investment in AI is expected to be lower in 2026 due to prior expenditures on computational resources, with a gradual increase anticipated as products enter clinical stages [27] Conclusion - 2025 is projected to be a challenging year for Anbiping, but the company aims to establish a solid foundation for the widespread application of its AI technologies in hospitals starting in 2026, ensuring sustainable business growth [31]

Group 1 - The A-share market experienced significant fluctuations on January 13, with the medical device ETF (562600) showing strong performance, rising by 1.58% [1] - The medical technology sector is gaining momentum, driven by AI applications in healthcare, with companies like Di'an Diagnostics hitting the daily limit and Jiukang Bio rising by 12.86% [1] - The medical device ETF (562600) has seen a net inflow of 140 million yuan over the past five trading days, indicating investor confidence in the medical technology sector [1] Group 2 - The medical device ETF (562600) is a key tool for investing in cutting-edge medical technology, tracking the CSI All-Share Medical Device Index, with a significant 23.8% weight in brain-computer interface stocks [2] - The ETF has a high industry exposure of 89.2%, including leading companies like Mindray Medical, United Imaging, and Di'an Diagnostics, effectively capturing the benefits of niche market growth [2] - Investors can participate in the medical device ETF through low-threshold options like the Huaxia CSI All-Share Medical Device ETF Initiated Link A (021250) and C shares (021251) for long-term growth opportunities [2]

Investment Rating - The report maintains an "Accumulate" rating for the in vitro diagnostics industry [7]. Core Views - The in vitro diagnostics (IVD) market is experiencing significant growth, with the domestic biochemical diagnostics sector having largely completed its localization process. The report suggests focusing on the growth potential in immunodiagnostics, particularly in chemiluminescence and molecular diagnostics such as PCR [4][54]. - Recent policy changes in Chongqing regarding pathology service pricing are expected to streamline and clarify pricing structures, which may enhance the role of pathology in precision medicine [4][54]. Summary by Sections Industry Performance - The pharmaceutical and biological sector rose by 7.81% this week, ranking 6th among 31 primary industries. The in vitro diagnostics sector specifically increased by 8.52% [9][18]. - The medical services sub-sector reported a 12.34% increase, while other related sectors also showed positive growth [18][19]. Valuation Metrics - As of the end of the week, the in vitro diagnostics sector had a PE ratio of 41.66X, with a one-year maximum of 41.97X and a minimum of 20.96X. The current PB ratio stands at 1.90X, with a one-year maximum of 2.01X and a minimum of 1.53X [3][28]. - The PE ratio increased by 3.30X and the PB ratio by 0.15X compared to the previous week [28]. Company Performance - Top-performing companies in the medical services sector include Anbiping (+39.5%), Rejing Biological (+27.1%), and Botuo Biological (+19.0%). Conversely, Mingde Biological (-2.2%) and others showed weaker performance [2][23].

Core Viewpoint - The introduction of AI in medical settings raises significant questions regarding responsibility and accountability, particularly when AI and inexperienced doctors provide differing treatment recommendations [1][2]. Group 1: Responsibility and Accountability - The integration of AI in healthcare necessitates a clear definition of responsibility boundaries and risk-bearing entities, as doctors assume dual roles of "principal" and "agent" [2]. - Current discussions emphasize the importance of establishing responsibility recognition in AI applications, especially as AI penetrates grassroots medical institutions more rapidly than in top-tier hospitals [2][3]. - Despite AI's capabilities, the ultimate responsibility for medical decisions remains with the doctors, as AI is currently viewed as an auxiliary diagnostic tool [2][3]. Group 2: AI in Healthcare Industry - AI is increasingly being adopted by various tech companies in the healthcare sector, with notable developments such as Ant Group's AI doctor assistant product "Ant Aifu" and Huawei's establishment of a medical team focusing on AI-assisted diagnosis [3]. - Companies like JD.com are also enhancing their healthcare services by integrating AI applications, such as the "Kangkang" AI medical mini-program within their health app [3].

Core Viewpoint - Anbiping (688393) has experienced a decline in stock price and market capitalization, with significant shareholder reductions and developments in its business related to digital pathology and AI-assisted diagnostics [1][2][3]. Group 1: Stock Performance and Shareholder Changes - As of December 26, 2025, Anbiping's stock closed at 23.99 yuan, down 3.85% from the previous week [1]. - The total market capitalization of Anbiping is 2.217 billion yuan, ranking 121 out of 127 in the medical device sector and 5001 out of 5181 in the A-share market [1]. - From December 1 to December 30, 2025, major shareholders reduced their holdings by a total of 685,800 shares, representing 0.7329% of the company's total equity [2]. Group 2: Institutional Research Insights - The National Healthcare Security Administration's new guidelines on pathology services are relevant to Anbiping, particularly regarding digital slide scanning and case report uploads, which could incur penalties if not provided [3]. - Anbiping's cervical cytology product is currently in the registration process, with the potential for new revenue streams from auxiliary diagnostic services [3]. - The company has over 300 medical institutions collaborating on its scanning equipment as of the first half of 2025 [4]. Group 3: AI and Digital Tools in Diagnostics - The integration of AI in pathology diagnostics is expected to enhance efficiency, with previous tests showing a reduction in diagnosis time from 218 seconds per slide to 30 seconds [6][7]. - Anbiping plans to negotiate with local healthcare and pricing departments to implement new pricing structures for AI-assisted diagnostics [5][6]. - The company is also expanding its AI capabilities beyond cervical cytology, with ongoing projects in immunohistochemistry and fluorescence scanning [7]. Group 4: Company Announcements - Anbiping will hold its first extraordinary general meeting of 2026 on January 14, 2026, to discuss the election of a non-independent director [8]. - The company announced the resignation of two senior executives and the nomination of a new non-independent director candidate, pending shareholder approval [8].

Core Viewpoint - The recent research meeting revealed that the National Healthcare Security Administration's new guidelines will impact the company's business, particularly in digital pathology and AI-assisted diagnostics, which are expected to enhance efficiency and create new revenue opportunities. Group 1: Regulatory Impact - The new guidelines from the National Healthcare Security Administration include a reduction policy for digital slices and diagnostic reports not provided, with a deduction of 5 yuan per slice, capped at 15 yuan for multiple slices [1][3] - The company is in the process of registering its cervical cytology AI Class III certification, which will allow for billing in AI-assisted diagnostics [1][3] - An additional charge for pathology specimens diagnosed within 24 hours has been introduced, which AI can help achieve by improving diagnostic efficiency [1][3] Group 2: AI Product Development - The company's AI product testing has shown a significant reduction in diagnosis time from 218 seconds per slice to 30 seconds per slice, with clinical results published in "Nature Communications" [2][9] - The AI's sensitivity for primary pathologists has improved from 0.717 to 0.858, demonstrating the effectiveness of the company's AI solutions [2][9] Group 3: Market Strategy and Sales Model - The company is exploring a sales model that includes increasing reagent sales through AI empowerment and selling software with annual usage fees to hospitals [6][7] - The integration of AI into the pricing structure of pathology diagnostics is expected to facilitate negotiations with local healthcare and pricing departments [6][7] Group 4: Equipment and Collaboration - The company offers a comprehensive solution that includes reagents, equipment, and scanners, with over 300 medical institutions collaborating on scanner usage by mid-2025 [4][5] - The transition from traditional to digital pathology in lower-tier hospitals is anticipated to drive demand for digital slice scanners [1][3] Group 5: Future AI Developments - The company has multiple projects in the immunohistochemistry AI space and has acquired a manufacturer of fluorescent scanners for FISH applications, with plans to begin certification by the end of 2026 [10]